Followers | 839 |
Posts | 120665 |
Boards Moderated | 13 |
Alias Born | 09/05/2002 |
Wednesday, September 19, 2007 4:11:02 AM
Oct 07: Start dosing in IDX-899 phase-1b monotherapy trial.
Nov 07: Data from selected Tyzeka post-marketing studies at AASLD conference.
Nov 07: 3Q07 financial results and CC.
4Q07: Preliminary data from IDX899 phase-1b trial.
4Q07: File IND for IDX102 or IDX184 second-generation HCV nucleoside analogs.
Feb 08: IDX899 phase-1b data at CROI conference.
Mar 08: 4Q07 financial results and CC with 2008 financial guidance.
May 08: Expiration of NVS-IDIX standstill agreement.
4Q08: File IND’s for HCV non-nucleoside polymerase inhibitor and HCV protease inhibitor.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
FEATURED North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM